Drug Trial Radar · NCT05901831
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
242
Actual
Start
Feb 26, 2024
Primary completion
Aug 20, 2025
Study completion Sep 15, 2025
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jun 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly, and type 1 diabetes. In people with type 1 diabetes, the body does not make enough of a hormone called insulin, resulting in high blood sugar levels that can cause damage to the kidneys. CKD often occurs together with or as a consequence of type 1 diabetes. The study treatment finerenone works by blocking certain proteins, called mineralocorticoid receptors. An increased stimulation of these proteins is thought to damage the kidneys and the heart. By lowering their stimulation, finerenone reduces the risk of kidney disease progressively getting worse. Finerenone is approved for doctors to prescribe to people with CKD and type 2 diabetes. In this study, researchers want to learn if finerenone works better than placebo in reducing the participants' kidney disease from getting worse when given in addition to standard of care (SOC) treatment. A placebo looks like a treatment but does not have any medicine in it. SOC is a procedure or treatment that medical experts consider most appropriate for a condition or disease. To find out how well finerenone works, the level of a protein (albumin) in the urine will be measured. Researchers also want to know how safe finerenone is. To do this, the researchers will collect the number of participants with: * medical problems (also called treatment-emergent adverse events (TEAEs)) * serious TEAEs. A TEAE is considered 'serious' when it leads to death, puts the participant's life at risk, requires hospitalization, causes disability, causes a baby being born with medical problems, or is medically important * higher than normal blood levels of potassium (hyperkalaemia). Depending on the treatment group, the participants will either take finerenone or placebo, Importantly, the participants will also continue to take their regular SOC medicines. The participants will be in the study for up to 7.5 months and will take the study treatments for 6 months. During the study, they will visit the study site at least 6 times. The study team will: * collect blood and urine samples * check the participants' vital signs such as blood pressure and heart rate * do a physical examination including height and weight * check the participants' heart health by using an electrocardiogram (ECG) * do pregnancy tests in women of childbearing potential
Conditions
- Chronic Kidney Disease
- Type 1 Diabetes Mellitus
Interventions
FinerenoneDrug
Dose A, Dose B, oral
PlaceboOther
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in UACR From Baseline (Ratio to Baseline) Over 6 MonthsTime frame: From baseline to Month 6
Locations
79 sites in 9 countries. Site status is shown where the registry gives one.
Southwest Kidney Institute, PLC - Suprise
Surprise, Arizona
Stanford Endocrinology Clinic
Stanford, California
Touro University California - Metabolic Research Center
Vallejo, California
UHealth Diabetes Research Center - Miami
Miami, Florida
AdventHealth Translational Research Institute
Orlando, Florida
CTR Oakwater, LLC
Orlando, Florida
Hanson Clinical Research Center, Inc.
Port Charlotte, Florida
Jedidiah Clinical Research
Tampa, Florida
Metabolic Research Institute, Inc.
West Palm Beach, Florida
Grady Memorial Hospital - Endocrinology
Atlanta, Georgia
Northwestern University | Feinberg School of Medicine - Division of Endocrinology, Metabolism and Molecular Medicine
Chicago, Illinois
UChicago Medicine Kovler Diabetes Center
Chicago, Illinois
Preventive Intervention Center - Endocrinology
Iowa City, Iowa
Wichita Nephrology Group, PA
Wichita, Kansas
Omega Clinical Research - Metairie
Metairie, Louisiana
MedStar Health Research Institute
Hyattsville, Maryland
Joslin Diabetes Center
Boston, Massachusetts
MU Health Care - University Hospital - Endocrinology
Columbia, Missouri
Center for Advanced Medicine - Diabetes Center
St Louis, Missouri
UNC Endocrinology, Diabetes, and Obesity Clinical Research Unit
Chapel Hill, North Carolina
Physicians East, P.A.- W. H. Smith - Endocrinology
Greenville, North Carolina
Accellacare - Wilmington
Wilmington, North Carolina
Cleveland Clinic - Main Campus - Endocrinology
Cleveland, Ohio
OHSU Physicians Pavillion - Endocrinology
Portland, Oregon
UT Health San Antonio - Medical Arts & Research Center - Endocrinology
San Antonio, Texas
Consano Clinical Research, LLC.
San Antonio, Texas
EVMS Strelitz Diabetes Center
Norfolk, Virginia
Providence Medical Research Center
Spokane Valley, Washington
Richmond Road Diagnostic and Treatment Centre | Clinical Trials Unit
Calgary, Alberta, Canada
Alberta Diabetes Institute | Clinical Research Unit (CRU)
Edmonton, Alberta, Canada
Toronto General Hospital - University Health Network, Renal Physiology laboratory
Toronto, Ontario, Canada
Research Institute of the McGill University Health Centre | McConnell Centre for Innovative Medicine
Montreal, Quebec, Canada
Centre hospitalier universitaire de Québec (CHUQ) | Cardiology
Québec, Quebec, Canada
Peking University People's Hospital
Beijing, Beijing Municipality, China
Southern Medical University - Nanfang Hospital (Southern Hospital)
Guangzhou, Guangdong, China
Zhongshan People's Hospital
Zhongshan, Guangdong, China
The 4th Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
The Central Hospital of Wuhan, Tongji Medl Collg Huazhong...
Wuhan, Hubei, China
Huai'an First People's Hospital, Nanjing Medical University
Huai'an, Jiangsu, China
Nanjing Medical University (NMU) - The Second Affiliated Hospital
Nanjing, Jiangsu, China
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.